Literature DB >> 3910220

Phase I study and pharmacokinetics of intraperitoneal carboplatin.

J G McVie, W ten Bokkel Huinink, R Dubbelman, H Franklin, W van der Vijgh, I Klein.   

Abstract

In the early stages of this phase I study the tolerance of carboplatin intraperitoneally was good. Pharmacokinetic profiles suggest a possible therapeutic advantage for giving the drug intraperitoneally for the treatment of tumour nodules situated in the peritoneum. The extent of penetration of carboplatin through tumour nodules has not yet been assessed but tumour nodules are being processed for nuclear activation analysis.

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 3910220     DOI： 10.1016/0305-7372(85)90016-7

Source DB:  PubMed          Journal:  Cancer Treat Rev        ISSN： 0305-7372            Impact factor:   12.111


  9 in total

1.  Preliminary observations of intraperitoneal carboplatin pharmacokinetics during a phase I study of the Northern California Oncology Group.

Authors:  M W DeGregorio; B L Lum; W M Holleran; B J Wilbur; B I Sikic
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

2.  Pharmacokinetics of platinum in cancer patients treated with carboplatin in combination with high-dose methotrexate.

Authors:  A el-Yazigi; M Amer; C R Martin
Journal:  Pharm Res       Date:  1989-06       Impact factor: 4.200

Review 3.  Clinical pharmacokinetics of carboplatin.

Authors:  W J van der Vijgh
Journal:  Clin Pharmacokinet       Date:  1991-10       Impact factor: 6.447

4.  Pharmacokinetics of carboplatin after intraperitoneal administration.

Authors:  F Elferink; W J van der Vijgh; I Klein; W W ten Bokkel Huinink; R Dubbelman; J G McVie
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

5.  Combination treatment of cis- and carboplatin in cancers restricted to the peritoneal cavity in the rat.

Authors:  G Los; L Tuyt; M van Vugt; J Schornagel; H M Pinedo
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

6.  Penetration of carboplatin and cisplatin into rat peritoneal tumor nodules after intraperitoneal chemotherapy.

Authors:  G Los; E M Verdegaal; P H Mutsaers; J G McVie
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

Review 7.  Carboplatin. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the treatment of cancer.

Authors:  A J Wagstaff; A Ward; P Benfield; R C Heel
Journal:  Drugs       Date:  1989-02       Impact factor: 9.546

Review 8.  Intraperitoneal therapy in the management of ovarian carcinoma.

Authors:  M Markman; T Hakes; B Reichman; W Hoskins; S Rubin; W Jones; L Almadones; J L Lewis
Journal:  Yale J Biol Med       Date:  1989 Jul-Aug

9.  Sequence dependence of the hyperthermic potentiation of carboplatin-induced cytotoxicity and intracellular platinum accumulation in HeLa cells.

Authors:  T Kusumoto; Y Maehara; H Baba; I Takahashi; H Kusumoto; S Ohno; K Sugimachi
Journal:  Br J Cancer       Date:  1993-08       Impact factor: 7.640
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.